Finance

Lists
MANE:NYSE
Veradermics Inc
115,07 $
+1,41%
(+1,60) 1D
115,07 $
0,00% (0,00)
After hours
Closed: 15 қаз., 16:00:03 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MANE...
Open
112,74 $
High
115,99 $
Low
111,05 $
Mkt. cap
4,81 млрд
Avg. vol.
834,60 м.
Volume
687,01 м.
52-wk high
136,72 $
52-wk low
32,00 $
EPS
-3,35 $
No. of employees
37
Open
112,74 $
High
115,99 $
Low
111,05 $
Mkt. cap
4,81 млрд
Avg. vol.
834,60 м.
Volume
687,01 м.
52-wk high
136,72 $
52-wk low
32,00 $
EPS
-3,35 $
No. of employees
37
News stories
From web sources and news partners
About Veradermics Inc
CEO-
Employees37
Founded2019
HeadquartersНью Хэвен, Коннектикут, Америка Құрама Штаттары
SectorPharmaceutical industry
Analyst ratings
Based on 4 analysts giving stock ratings to MANE in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for MANE in the last 3 months.
Highest
Current 115,07 $
182,00 $ (+58,16%)
Average
169,00 $ (+46,87%)
Lowest
160,00 $ (+39,05%)
Analyst
Recommendation
Action
Price target
Projected
Date
Geoff Meacham
Citi
Buy
Maintained
160,00 $
+39%
10/15/2026
Roger Song
Jefferies
Buy
Maintained
182,00 $
+58,2%
09/08/2026
Unknown Analyst
Jefferies
Buy
Maintained
182,00 $
+58,2%
09/08/2026
Serge Belanger
Needham
Buy
Maintained
164,00 $
+42,5%
08/12/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
170,00 $
+47,7%
08/11/2026
Mayank Mamtani
B. Riley Securities
Buy
Initiated
170,00 $
+47,7%
07/15/2026
Marc Goodman
Leerink Partners
Buy
Initiated
75,00 $
-34,8%
03/02/2026
Prakhar Agrawal
Cantor Fitzgerald
Buy
Initiated
-
-
03/01/2026
Last report
2026 ж. 11 там.
Fiscal period
Q2 2026
-0,58 $ / -0,64 $
+9,56%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. мау.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
14,33 млн
18,19 млн
20,92 млн
18,61 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,74 млн
4,82 млн
8,94 млн
10,95 млн
Operating expense
16,07 млн
23,01 млн
29,86 млн
29,55 млн
Total operating expenses
16,07 млн
23,01 млн
29,86 млн
29,55 млн
Operating income
-16,07 млн
-23,01 млн
-29,86 млн
-29,55 млн
Other non operating income
325,00 м.
258,00 м.
149,00 м.
1,21 млн
EBT including unusual items
-15,64 млн
-21,85 млн
-27,23 млн
-23,50 млн
EBT excluding unusual items
-15,64 млн
-21,85 млн
-27,23 млн
-23,50 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-15,64 млн
-21,85 млн
-27,23 млн
-23,50 млн
Net profit margin
-
-
-
-
Earnings per share
-
-104,54
-1,32
-0,58
Interest and investment income
103,00 м.
906,00 м.
2,48 млн
4,84 млн
Interest expense
-
-
-
-
Net interest expenses
103,00 м.
906,00 м.
2,48 млн
4,84 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google қолданбалары